Prepare For What Investors & the FDA Are Really Looking For | Tim Looney

Founder-friendly, investor-real talk. In his second visit to LSC, Tim Looney (Northeast Biomedical) explains how to turn prototypes into investor-ready products: DHF done right, phased engineering plans, avoiding “jam it through” FDA myths, and picking the right money.

Investors aren’t funding your cool device—they’re underwriting your ability to de-risk it. In this episode, Tim Looney (President & CEO, Northeast Biomedical) returns, breaking down the investor lens for med-tech: show a credible timeline, a traceable design history file, and a stage-gated plan that prevents “surprise” testing at the eleventh hour.

We dig into DHF essentials, how to avoid endless prototyping, and why “let the FDA tell us what’s missing” is the slowest, riskiest strategy. Tim shares a standout success—an EU class III clearance in two weeks thanks to a meticulous dossier—and a cautionary tale where a buyer inherited gaps and had to backfill under FDA scrutiny.

We also talk capital: why the color of money matters, how to spot investors who add operational value, and the signaling power of ISO 13485 systems, external advisors, and documented learnings.

If you’re preparing for investors—or realizing you should have prepared earlier—connect with Bill. Translate conviction into execution-ready roadmaps and pressure-test investor fit before urgency takes over. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/

Follow Bill:   / founderandcdo  

Contact Bill: https://meshagency.com/lets-connect/

Video Podcast:    / @billschickfcmo  

Audio Podcast: https://www.buzzsprout.com/2380430

Follow Tim: / tlooney